These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 2442312)

  • 21. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
    Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
    J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
    Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
    J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intracavitary chemotherapy for malignant disease confined to body cavities.
    Markman M
    West J Med; 1985 Mar; 142(3):364-8. PubMed ID: 3887760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical effects induced by intratumoral administration of anti-cancerous drugs in skin malignant tumors].
    Ishihara K
    Gan To Kagaku Ryoho; 1989 Feb; 16(2):173-9. PubMed ID: 2465739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraperitoneal chemotherapy in the management of malignant disease.
    Markman M
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):142-8. PubMed ID: 12113122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraperitoneal chemotherapy in the management of colon cancer.
    Markman M
    Semin Oncol; 1999 Oct; 26(5):536-9. PubMed ID: 10528901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [ BCG-immunotherapy and bladder cancer].
    Rischmann P
    Prog Urol; 2008 May; 18 Suppl 5():S93. PubMed ID: 18585633
    [No Abstract]   [Full Text] [Related]  

  • 28. [Intraperitoneal chemotherapy in ovarian carcinoma].
    Piura B
    Harefuah; 2001 Sep; 140(9):844-9, 894, 893. PubMed ID: 11579736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
    Huben RP
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regional cancer chemotherapy.
    Ensminger WD; Gyves JW
    Cancer Treat Rep; 1984 Jan; 68(1):101-15. PubMed ID: 6692422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.
    Joudi FN; Smith BJ; O'Donnell MA; Konety BR
    J Urol; 2006 May; 175(5):1634-9; discussion 1639-40. PubMed ID: 16600718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraperitoneal chemotherapy in ovarian cancer: an update.
    Runowicz CD
    Cancer J; 2008; 14(1):7-9. PubMed ID: 18303475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic therapy of melanoma with cytokines and lymphocytes.
    Bear HD; Hamad GG; Kostuchenko PJ
    Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and treatment of superficial bladder cancer: an update.
    Crawford ED
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):1-9. PubMed ID: 8727804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological response modifiers as adjuvants in monoclonal antibody-based treatment (review).
    Guadagni F; Roselli M; Nieroda C; Dansky-Ullmann G; Schlom J; Greiner JW
    In Vivo; 1993; 7(6B):591-9. PubMed ID: 8193280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Editorial comment on: prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
    Sylvester RJ
    Eur Urol; 2008 May; 53(5):1002. PubMed ID: 17950990
    [No Abstract]   [Full Text] [Related]  

  • 38. Cytotoxic intracavitary chemotherapy.
    Markman M
    Am J Med Sci; 1986 Mar; 291(3):175-9. PubMed ID: 3513565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug agency jumps TNF gun.
    Beardsley T
    Nature; 1985 May 16-22; 315(6016):175. PubMed ID: 3889653
    [No Abstract]   [Full Text] [Related]  

  • 40. Intraperitoneal therapy in the management of ovarian carcinoma.
    Markman M; Hakes T; Reichman B; Hoskins W; Rubin S; Jones W; Almadones L; Lewis JL
    Yale J Biol Med; 1989; 62(4):393-403. PubMed ID: 2688324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.